Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...
Business Insider1mon
Immuneering to present data from Phase 2a trial of IMM-1-104 in early January
PD and safety data from the Phase 1 portion of the company’s Phase 1/2a trial of IMM-6-415. Details of how to access the Investor Event will be provided in due course. Published first on TheFly ...
Yahoo Finance6d
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
IMM-6-415 is an oral, twice-daily deep cyclic inhibitor of MEK currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The company’s development ...